Twist Bioscience Corporation Common Stock

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 979 full-time employees. The company went IPO on 2018-10-31. The firm's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The firm has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.